Molecular Markers of Prognosis in Colorectal Cancer Patients

This study has been completed.
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust Identifier:
First received: September 20, 2005
Last updated: May 30, 2013
Last verified: May 2013

To correlate the molecular profile of a series of defined CRCs with prognosis and toxicity.

Colorectal Cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Molecular Markers of Prognosis in Colorectal Cancer Patients

Resource links provided by NLM:

Further study details as provided by Royal Marsden NHS Foundation Trust:

Enrollment: 103
Study Start Date: November 2003

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The GI unit Royal Marsden Hospital NHS trust (RMHNHST) has co-ordinated and published results from a large multicentre randomised clinical trial of patients with locally advanced CRC (Saini et al. 2003). A total of 716 patients Dukes' B and C CRC operated with curative intent were randomised to receive either bolus or infusional 5FU regimes. Patients treated at the RMHNHST made up the majority of the total sample cohort (n=550). Analysis of results after a median of 19.8 months follow-up showed that infused 5-FU given over 12 weeks resulted in similar survival to bolus 5-FU and FA over a six-month period (log rank p=0.764). There was, however, significantly less toxicity associated with the infusional regime.


Inclusion Criteria:

  • All patients participating in the RMHNHST study of infusional versus bolus 5FU (Saini et al. 2003).
  Contacts and Locations
Please refer to this study by its identifier: NCT00220142

United Kingdom
Royal Marsden Hospital
Sutton, Surrey, United Kingdom, SM2 5PT
Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Principal Investigator: David Cunningham Royal Marsden NHS Foundation Trust
  More Information

No publications provided

Responsible Party: Royal Marsden NHS Foundation Trust Identifier: NCT00220142     History of Changes
Other Study ID Numbers: 2348
Study First Received: September 20, 2005
Last Updated: May 30, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases processed this record on April 16, 2014